Business Wire Industry News

Friday, May 20, 2022

Aurinia Presents Results from the Two-Year AURORA 2 Continuation Study at the 2022 European Renal Association (ERA) Congress

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, today presented for the first time the results of the AURORA 2 continuation study evaluating the long-term safety and tolerability of LUPKYNIS™ (voclosporin) for the treatment of adults with active lupus nephritis (LN), a serious complication in patients with systemic lupus

Friday, May 20, 2022

Zymeworks’ Board of Directors Unanimously Rejects Unsolicited, Non-Binding Proposal

VANCOUVER, British Columbia & SEATTLE--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that its Board of Directors, after thorough consultation with its financial and legal advisors, unanimously determined that the unsolicited, opportunistic, non-binding proposal from an activist shareholder, All Blue Falcons FZE (“All Blue”), and its affiliates to purchase Zymeworks for $10.50 p

Friday, May 20, 2022

Tentarix Biotherapeutics Announces the Strengthening of its Leadership and Advisory Teams

SAN DIEGO & VANCOUVER, British Columbia--(BUSINESS WIRE)--Tentarix Biotherapeutics LP, a biotechnology company developing first-in-class targeted, conditional antibody-based multifunctional biotherapies, today announced the formation of a Scientific Advisory Board (SAB) and appointments to its Board of Directors and leadership team. The SAB, initially comprised of three experts in immunology, cancer biology and protein engineering, will provide strategic and scientific counsel to advance the co

Thursday, May 19, 2022

VBI Vaccines Presented Health Economics and Outcomes Research for PreHevbrio™ at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2022

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that health economics and outcomes research (HEOR) comparing the cost-effectiveness of the Company’s 3-antigen hepatitis B vaccine (HBV), PreHevbrio™ [Hepatitis B Vaccine (Recombinant)], to a single-antigen HBV vaccine, Engerix-B®, among adults in the U.S. was presented in a poster at the Inter

Wednesday, May 18, 2022

Appili Therapeutics Announces Pricing of Overnight Marketed Equity Offering

HALIFAX, Nova Scotia--(BUSINESS WIRE)--Appili Therapeutics Inc. (TSX: APLI) (the “Company” or “Appili”) is pleased to announce today that it has priced its previously announced overnight marketed offering of equity securities (the "Offering"). Pursuant to the Offering, Appili will issue 50,000,000 units of the Company ("Units") at a price of C$0.09 per Unit (the “Offering Price”) for gross proceeds of C$4,500,000. Each Unit is comprised of one Class A common share of the Company (a "Common Shar

Tuesday, May 17, 2022

Appili Therapeutics Announces Overnight Marketed Equity Offering

HALIFAX, Nova Scotia--(BUSINESS WIRE)--Appili Therapeutics Inc. (TSX: APLI) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases, today announced that it will undertake an overnight marketed public offering (the "Offering") of units (the "Units"), comprised of Class A common shares and Class A common share purchase warrants ("Warrants"). The Offering is to be effected on a best efforts agency basis in each Province of Canada (other than Qu

Tuesday, May 17, 2022

ZS and Quartic to Accelerate Manufacturing Digitalization in Life Sciences and Healthcare

EVANSTON, Ill.--(BUSINESS WIRE)--The global professional services firm ZS announced today it is making a multimillion-dollar investment in and partnering with Quartic.ai, an enterprise-scale AI platform that advances autonomous manufacturing. This partnership aims to improve how manufacturers in life sciences and healthcare use technology, data and artificial intelligence (AI) to speed up the launch of products and meet sustainability goals. ZS and Quartic will collaborate to help drive resilie

Tuesday, May 17, 2022

Cybin to Participate in NYSE Trading Bell Ceremony on May 18, 2022

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM” is pleased to announce that it will participate in the morning trading bell ceremony on May 18, 2022 at the New York Stock Exchange (“NYSE”) in New York City. Cybin, whose shares commenced trading on the NYSE American on August 5, 2021, was the first psychedelics company to be listed on the NYSE. “We are delighted to be

Monday, May 16, 2022

Perimeter Medical Imaging AI to Present at ROTH Canada Showcase Day

TORONTO & DALLAS--(BUSINESS WIRE)--Perimeter Medical Imaging AI, Inc. (TSX-V:PINK)(OTC:PYNKF) (FSE:4PC) (“Perimeter” or the “Company”), a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs, announced it will participate in investor meetings and host a company presentation at the ROTH Canada Showcase Day to be held on May 17, 2022 in New York, NY. Company Presentation/Webcast Details:    

Monday, May 16, 2022

Miravo Healthcare™ Announces Director Election Results of its Annual Meeting of Shareholders

MISSISSAUGA, Ontario--(BUSINESS WIRE)--Nuvo Pharmaceuticals Inc. (TSX:MRV; OTCQX:MRVFF) d/b/a Miravo Healthcare (Miravo or the Company) a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, today announced that at its 2022 Virtual Annual Meeting of Shareholders held on May 16, 2022 (the Meeting), all nominees listed in the management proxy circular dated April 8, 2022 were elected as directors of the Company. The detailed results of the vote

Monday, May 16, 2022

AESARA, Inc. to Expand European Presence into Zug, Switzerland

LONDON & CHAPEL HILL, N.C. & TORONTO--(BUSINESS WIRE)-- #Europe--AESARA (www.aesara.com) is pleased to announce expansion of its European operations by establishing a new hub in Zug, Switzerland, in May 2022. Gavin Outteridge, General Manager for AESARA Europe said, “Carefully selected for both customer proximity and access to talent, new AESARA operations in Switzerland strengthen our global and regional presence, complementing AESARA’s existing reach across North America and the United Kingdom.” Outter

Monday, May 16, 2022

Quebec’s Life Sciences Strategy 2022-2025: A Promising Plan for BIOQuébec’s Members and Quebec’s Life Sciences Industry

BROMONT, Québec--(BUSINESS WIRE)--BIOQuébec welcomes the tabling of the 2022-2025 Quebec Life Sciences Strategy (QLSS) which will support - and above all, foster - the growth of Quebec’s life sciences ecosystem. The second version of the QLSS features three major objectives, five areas of focus, and ten promising measures for the industry. “The QLSS is the result of an extensive consultation process that involved five working groups and several meetings attended by BIOQuébec’s management and se

Monday, May 16, 2022

Miravo Healthcare™ Announces First Quarter 2022 Results

MISSISSAUGA, Ontario--(BUSINESS WIRE)--Nuvo Pharmaceuticals Inc. (TSX:MRV; OTCQX:MRVFF) d/b/a Miravo Healthcare (Miravo or the Company), a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, today announced its financial and operational results for the three months ended March 31, 2022. For further details on the results, please refer to Miravo’s Management, Discussion and Analysis (MD&A) and Condensed Consolidated Interim Financial Stat

Monday, May 16, 2022

Aurinia Pharmaceuticals Announces Presentations at the 2022 ERA Congress and the 2022 EULAR Congress

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, today announced that data from multiple studies of LUPKYNIS™ (voclosporin) will be presented at the 59th European Renal Association (ERA) Congress and at the European Congress of Rheumatology, European Alliance of Associations for Rheumatology (EULAR) 2022. The 2022 ERA Con

Monday, May 16, 2022

Columbia Care Reports First Quarter 2022 Results

NEW YORK--(BUSINESS WIRE)--Columbia Care Inc. (NEO: CCHW) (CSE: CCHW) (OTCQX: CCHWF) (FSE: 3LP) (“Columbia Care” or the “Company”) today reported financial and operating results for the first quarter ended March 31, 2022. All financial information presented in this release is in U.S. GAAP, unaudited and in thousands of U.S. dollars, unless otherwise noted, and comparisons to prior quarter and prior year are made on an as-converted basis under U.S. GAAP, unless otherwise noted. “The results of t

Monday, May 16, 2022

Element Nutritional Sciences to Report Record Revenue in Q1 2022

BURLINGTON, Ontario--(BUSINESS WIRE)--Element Nutritional Sciences Inc. (CSE:ELMT; OTC:ELNSF; FRANKFURT:93X) (the “Company” or “Element”), is pleased to provide an update highlighting preliminary financial results for the first quarter ended March 31, 2022 (“Q1 2022”) and recent operational milestones. All amounts are expressed in Canadian dollars. Stuart Lowther, Chief Executive Officer, commented, “We expect Q1 2022 to be a milestone quarter for Element. We look forward to reporting record re